Many of the primary and secondary inflammatory cytokines and signaling pathways involved in CRS were markedly abrogated by zanubrutinib, including IL-1β, IL-6, IL-8, G-CSF, and MIP-1α (50–52). This evidence concerns the gene IL1B and congenital rubella syndrome.